San Francisco-based Evolv has launched a dietary supplement containing a peptide designed to engage GLP-1 and GIP receptors, positioning the product in what the company calls a "biomimetics" category between traditional supplements and prescription medications like Ozempic. Engineered Yeast Platform The supplement contains baker's yeast engineered to produce a peptide that interacts with GLP-1 and […]